Addition of Lactobacillus to Metronidazole in Treatment of CDAD

Withdrawn before enrolling · Phase 4

Conditions studied: Enterocolitis, Pseudomembranous Colitis, Antibiotic-associated Colitis

In brief

The purpose of this study is to determine whether dietary supplementation with Lactobacillus GG will reduce the rate of failure or relapse following treatment of CDAD with metronidazole.

Key facts

Study ID

NCT00304863

Run by

Michael E. DeBakey VA Medical Center

People needed

0

Starts

2008-08-01

Expected to finish

2010-07-31

Last updated by the study team

2017-05-10

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Subjects will be identified based on the diagnosis of CDAD. This diagnosis is made bases on the presence of diarrhea, fever, abdominal pain and/or leukocytosis together with a positive fecal assay for Clostridium difficile toxin

You may not qualify if…

• Patients who are unable to take oral medications and those with underlying gastrointestinal disease or colonostomy will be excluded.
• Patients currently taking penicillins, cephalosporins, quinolones or tetracyclines will be excluded because these drugs are active against Lactobacillus.

Where it is running

• Michael E. DeBakey Veterans Affairs Medical Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.